3 results
Primary:* To determine if alisertib improves overall response rate (ORR; complete response [CR] plus partial response [PR]) versus a selection of single agents in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL)* To determine…
Primary Objective:Assess the safety and explore the biologically effective dose (BED) and/or the maximum tolerated dose (MTD) and/or the recommended Phase II dose (RP2D) of AZD4573 in patients with relapsed or refractory haematological…
To demonstrate that oral anticoagulation with the NOAC edoxaban is superior to current therapy (antiplatelet therapy or no therapy depending on cardio-vascular risk) to prevent stroke, systemic embolism, or cardiovascular death in patients with AHRE…